Effect of cyclooxygenase activity on Amloid

John Oates, MD
Vanderbilt Univ. Medical Center (Nashville, TN)
Year Awarded:
2004
Grant Duration:
August 1, 2004 to July 31, 2007
Disease:
Alzheimer's Disease
Award Amount:
$500,000
Grant Reference ID:
A2004517
Award Type:
Standard
Award Region:
US Southeastern

Effect of cyclooxygenase activity on Amloid

Details


This study focuses on the effects of an enzyme, cyclo-oxygenase, on amyloid beta, the protein fragment that aggregates into plaques in the brains of Alzheimer's patients. The process by which amyloid beta accumulates and clumps together to create plaques is not well understood, but scientists think it is central to the development of Alzheimer's disease. The study may shed light on how non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin and ibuprofen are thought to lower the risk of developing Alzheimer's disease. NSAIDs are known to inhibit the actions of cyclo-oxygenases, and the scientists believe that if they can succeed in creating a more powerful compound to block cyco-oxygenase activity, it could lead to a drug that would actually halt the disease. Current Alzheimer's drugs treat the symptoms, but no drug has been found yet to stop the progression of Alzheimer's disease.

Publications

Zagol-Ikapitte, I., Masterson, T.S., Amarnath, V., Montine, T.J., Andreasson, K.I., Boutaud, O., Oates, J.A. (2005) Prostaglandin H2-derived adducts of proteins correlate with Alzheimer's disease severity. Journal of Neurochemistry. 94:1140-1145.  

Boutaud, O., Andreasson, K.I., Zagol-Ikapitte, I., Oates, J.A. (2005) Cyclooxygenase-dependent lipid-modification of brain proteins. Brain Pathology. 15:139-142.  

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Please enter your first name.
Please enter your last name.
Keep me informed about: *
Please select at least one.
You must select at least one disease category.